Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

  • Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 6/1/18 (What's New)

Summary

  • Significant drug–drug interactions complicate concomitant treatment of HIV infection and TB
  • Cotreatment of HIV and TB requires careful consideration of potential drug interactions and the need for patient monitoring (Table 8)
    • Rifampin and Antiretrovirals
    • Efavirenz-based ART is the recommended option for patients receiving rifampin-based TB regimen
    Rifabutin and Antiretrovirals
      Rifapentine and Antiretrovirals
        Other Antimycobacterial Agents and Antiretrovirals

        Action required

        Keywords: Drug-Drug Interactions, Pharmacokinetics, Tuberculosis

        ©2018 Clinical Care Options, LLC. All Rights Reserved.

        The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.